As part of its policy,the health ministry to widen the list of essential medicines that will be subject to a price cap,India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms and aimed at improving affordability to patients.
- who is drug pricing regulator in india? The National Pharmaceutical Pricing Authority (NPPA) .
The drugs that will become cheaper would include atorvastatin, gliclazide, glimepiride, heparin and metolazone among others.
- The government had last year fixed the prices of 652 drugs under national list of essential medicines (NLEM) under the Drug Price Control Order (DPCO).
- what will happen now?multinational pharmaceutical companies would have to take a major hit on their margins.
Comments
Post a Comment